Pyrazinamide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PYRAZINAMIDE | — | 1971-06-03 | fda.gov ↗ |
Trials 73 · started per year
Also used as a comparator or background therapy in 66 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00004736 Background | — | HIV infectious disease, tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03678688 Comparator | Oct 2018 → Feb 2022 | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02958709 Background | Feb 2017 → Nov 2020 | meningeal tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT07656012 Background | Sep 2026 → Sep 2030 expected | tuberculosis | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07595042 Background | Jul 2026 → Jun 2029 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07350174 Comparator | Mar 2026 → Mar 2028 expected | meningeal tuberculosis | BioVersys AG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07073638 Background | Oct 2025 → Sep 2026 expected | pulmonary tuberculosis | Thirty Respiratory Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06446245 Background | Aug 2025 → Nov 2027 expected | meningeal tuberculosis | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT06917495 Background | Apr 2025 → Dec 2027 expected | tuberculosis, spinal | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06192160 Comparator | Mar 2025 → Nov 2026 expected | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT05630872 Background | Feb 2024 → May 2025 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT06199921 Comparator | Jan 2024 → Mar 2026 overdue | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05556746 Comparator | Nov 2023 → Jun 2025 overdue | HIV infectious disease, pulmonary tuberculosis | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06224036 Comparator | Oct 2023 → Mar 2024 | drug-resistant tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06058299 Comparator | Oct 2023 → Dec 2024 overdue | pulmonary tuberculosis | Global Alliance for TB Drug Development | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05534750 Comparator | Apr 2023 → Apr 2026 overdue | multidrug-resistant tuberculosis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT04179500 Background | Sep 2021 → Jun 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT04930744 Background | Aug 2021 → Apr 2025 | coinfection, pulmonary tuberculosis | University of Massachusetts, Worcester | Completed | No outcome recorded |
| Phase 2 | NCT04504851 Background | Aug 2020 → Mar 2021 | pulmonary tuberculosis | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT04176250 Comparator | Jan 2020 → Oct 2022 | pulmonary tuberculosis | Gates Medical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03927313 Background | Jun 2019 → Mar 2021 | HIV infectious disease, meningeal tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 2 | NCT03563599 Comparator | Jul 2018 → Sep 2019 | tuberculosis | Qurient Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02836483 Comparator | Dec 2016 → Jul 2019 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03281226 Comparator | Dec 2016 → Jun 2019 | AIDS, pulmonary tuberculosis | Fundação de Medicina Tropical Dr. Heitor Vieira Dourado | Unknown | No outcome recorded |
| Phase 2 | NCT01589497 Comparator | Jun 2015 → Jan 2016 | tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02256696 Background | Apr 2015 → May 2022 | pulmonary tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02365623 Background | Feb 2015 → Nov 2018 | multidrug-resistant tuberculosis | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 2 | NCT02279875 Comparator | Nov 2014 → Nov 2016 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT01601626 Background | Jul 2013 → Jan 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Terminated | No outcome recorded |
| Phase 2 | NCT02121314 Comparator | Jul 2013 → Apr 2014 | tuberculosis | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2 | NCT01785186 Background | Apr 2013 → Sep 2014 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 2 | NCT01516203 Comparator | Dec 2012 → Dec 2013 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01225640 Comparator | Aug → Dec 2011 | tuberculosis | Sequella, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01215851 Comparator | Oct 2010 → May 2011 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT00728507 Background | Nov 2009 → Apr 2013 | tuberculosis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00144417 Background | Feb 2006 → Jun 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00140309 Background | Jul 2003 → Dec 2005 | pulmonary tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT04721795 Comparator | Jan 2021 → Mar 2022 | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03474198 Background | Mar 2018 → Jan 2022 | pulmonary tuberculosis | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT02169882 Background | Dec 2014 → Nov 2016 | meningeal tuberculosis | Padjadjaran University | Completed | No outcome recorded |
| Phase 2/3 | NCT02467608 Background | Dec 2012 → Jan 2019 | pulmonary tuberculosis | Orient Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 315 trials | ||||||
| Phase 3 | NCT07076225 Background | Jul 2025 → Jan 2030 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06253715 Background | Jan 2025 → Sep 2027 expected | lymph node tuberculosis, pulmonary tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT06727864 Background | Jan 2024 → Dec 2027 expected | pulmonary tuberculosis | Kaohsiung Veterans General Hospital. | Recruiting | No outcome recorded |
| Phase 3 | NCT06081361 Comparator | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04951986 Background | Aug 2021 → Dec 2025 overdue | HIV infectious disease, tuberculosis | University of Cape Town | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04260477 Comparator | Mar 2021 → Jun 2025 overdue | multidrug-resistant tuberculosis, pulmonary tuberculosis | Institute of Tropical Medicine, Belgium | Recruiting | No outcome recorded |
| Phase 3 | NCT04145258 Background | Feb 2021 → Sep 2026 expected | meningeal tuberculosis | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT04485156 Background | Sep 2020 → Aug 2025 overdue | pulmonary tuberculosis | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04856644 Background | Jan 2020 → Dec 2023 overdue | pulmonary tuberculosis | Kaohsiung Veterans General Hospital. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04062201 Comparator | Aug 2019 → Apr 2024 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Wits Health Consortium (Pty) Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02581527 Background | Feb 2017 → Jan 2022 | pulmonary tuberculosis | St George's, University of London | Completed | No outcome recorded |
| Phase 3 | NCT02563327 Background | May 2016 → Aug 2021 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT02153528 Background | Nov 2014 → Aug 2017 | pulmonary tuberculosis | Damien Foundation | Completed | No outcome recorded |
| Phase 3 | NCT02120638 Comparator | Apr 2014 → Apr 2016 | multidrug-resistant tuberculosis | Huashan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00698334 Comparator | Apr 2006 → Sep 2010 | AIDS, tuberculosis | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT06403943 Background | May 2023 → Oct 2026 expected | pulmonary tuberculosis | Beijing Chest Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05306223 Background | May 2022 → Aug 2025 | multidrug-resistant tuberculosis | Beijing Chest Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03561753 Comparator | Dec 2017 → Dec 2019 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 4 | NCT02231229 Comparator | Jul 2014 → Jul 2018 | tuberculosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT04187469 Comparator | Mar 2020 → Feb 2023 | pulmonary tuberculosis | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03604848 Comparator | Aug 2018 → Aug 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT02554318 Background | Nov 2013 → Feb 2015 | pulmonary tuberculosis | University of Giessen | Completed | No outcome recorded |
| — | NCT01677871 Comparator | Sep 2012 → Sep 2014 | tuberculosis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT01344148 Background | Feb 2009 → Jun 2011 | AIDS | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 145 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pyrazinamide | “anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS],...” NCT02365623 ↗138“INTERVENTIONS: Patients were randomized to receive daily treatment with 4 drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) given as an FDC (n = 798 patients) or...” PMID 21486974 ↗ Apr 2011 “This product is a compound preparation, consisting of 0.15g of rifampicin (C43H58N4O12), 0.075g of isoniazid (C6H7N3O), 0.4g of pyrazinamide (C5H5N3O), and 0.275g of ethambutol...” NCT06224036 ↗ “Experimental arms are seven oral regimens with a five-drug combination of the following: bedaquiline, linezolid, a fluoroquinolone (moxifloxacin or levofloxacin), cycloserine,...” NCT05081401 ↗ “FDC intensive phase containing 150 mg of rifampicin, 75 mg of isoniazid not 300mg, 400 mg of pyrazinamide, and 275 mg of ethambutol, while FDC continuation phase containing...” NCT05005637 ↗ “The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.” NCT03561753 ↗ “This study aimed to quantify the influence of food on the pharmacokinetics of isoniazid, rifampicin, ethambutol and pyrazinamide in TB patients starting anti-TB treatment.” PMID 26661397 ↗ Dec 2015 “SOC plus 6 months of tuberculosis treatment (isoniazid, rifampicin, pyrazinamide, and ethambutol for 2 months, plus isoniazid and rifampicin for 4 subsequent months)” PMID 42468541 ↗ Jul 2026 “Pyrazinamide is part of interventional arms with bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ). Pyrazinamide is part of control regimen (HRZE).” NCT05766267 ↗ “The investigational MDR-END Plus regimen consists of oral anti-tuberculosis drugs including bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide.” NCT07675954 ↗ “RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months” NCT04117698 ↗ “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ “Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months.” NCT04721795 ↗ “8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin.” NCT07608172 ↗ “Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained” NCT02153528 ↗ “Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight)” NCT03281226 ↗ “including rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 15 - 20 mg/kg, ± pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day” NCT06446245 ↗ “The abbreviation of the name of the 3 drugs in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）” NCT03830671 ↗ “8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin” NCT04856644 ↗ “Patients with probable or definite TB meningitis (TBM) will all receive isoniazid and pyrazinamide at standard doses for 8 weeks.” NCT02958709 ↗ “Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days” NCT04176250 ↗ “Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months” NCT01677871 ↗ “Two months of isoniazid (H), ethambutol (E), rifampicin (R) and Pyrazinamide (Z) followed by HR(E) for another two months” NCT06727864 ↗ “10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.” NCT03927313 ↗ “Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)” NCT01225640 ↗ “isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin” NCT04145258 ↗ “Each tablet of Rifafour e-275® contains 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide and 275mg ethambutol.” NCT04044001 ↗ “Isoniazid (5 mg/kg/day); Rifampicin (10 mg/kg/day); Pyrazinamide (30 mg/kg/day); Ethambutol (20 mg/kg/day).” NCT07350174 ↗ “or an active control of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) or linezolid 600 mg BID.” PMID 34871098 ↗ Dec 2021 “Isoniazid (H) + rifampicin (R) + pyrazinamide (Z), ethambutol (E) for 8 weeks followed by HR for 18 weeks” NCT06058299 ↗ “Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol.” NCT03678688 ↗ “Anti-Tb Therapy: 2HREZ-4HRifb(H:Isoniazid，R:Rifampicin，E:Ethambutol，Z：pyrazinamide，Rifb:Rifabutin)” NCT01344148 ↗ “standard-dose of pyrazinamide (Z) 20-30 mg/kg daily + ethambutol (E) 15-20 mg/kg daily for 8 weeks” NCT04738812 ↗ “Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily” NCT03604848 ↗ “isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)” NCT06041919 ↗ “pyrazinamide ≤55kg 900mg daily, 55-71kg 1200mg daily, \>71kg 1600mg daily; ethambutol” NCT05401071 ↗ “daily rifapentine (R) and moxifloxacin (M) plus isoniazid (H) and pyrazinamide (P)” NCT05630872 ↗ “other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin” NCT02169882 ↗ “Isoniazid (H) , Rifampicin (R), Pyrazinamide (Z) and Ethambutol (E)” NCT06153069 ↗ “bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide” NCT07227779 ↗ “moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide” PMID 29519716 ↗ Mar 2018 “PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)” NCT05278988 ↗ “RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)” NCT03563599 ↗ “isoniazid, high dose isoniazid, pyrazinamide, ethambutol” NCT03237182 ↗ “Ethambutol; isoniazid; rifampicin; pyrazinamide” NCT04260477 ↗ “Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd” NCT02128308 ↗ “Pyrazinamide 20-25mg / kg / day for 7 days” NCT05534750 ↗ “evaluate WBA of PNU with pyrazinamide” NCT00990990 ↗ “pyrazinamide [Z]; 1000~2000mg daily” NCT02467608 ↗ “Pyrazinamide 1500 mg daily” NCT03867136 ↗ “pyrazinamide (Z / PZA)” NCT02231229 ↗ “pyrazinamide (1.5g)” NCT06403943 ↗ “Pyrazinamide (PZA):” NCT07268664 ↗ “Pyrazinamide” NCT02099240 ↗ |
| Known as | .alpha.-pyrazinamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Aldinamid | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Aldinamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Eprazin | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Farmizina | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Isopas | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | MK-56 | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Novamid | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | NSC-14911 | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pirazimida | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pirazinamid | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pirazinamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pirilene | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pyrafat | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pyramizade | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pyrazide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pyrazinamide (Z) | “Pyrazinamide (Z)” NCT07656012 ↗ |
| Known as | Pyrazinamide component of rifater | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | pyrazinamide tablets | “pyrazinamide tablets” NCT02331823 ↗ |
| Known as | Pyrazinamidum | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Pyrazine carboxylamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | PYZ | “AI-optimised combination drug regimen consisting of Pyrazinamide (PYZ) and Hydroxychloroquine (HCQ) for treating drug-sensitive pulmonary tuberculosis.” NCT07467252 ↗ |
| Known as | PZA | “Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are...” NCT00816426 ↗11“Arm 1 participants will receive high-dose rifampicin for 8 weeks plus ethambutol at standard doses, in addition to standard doze pyrazinamide (PZA) and isoniazid.” NCT02958709 ↗ “The abbreviation of the name of the 3 drugs in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）” NCT03830671 ↗ “pyrazinamide (PZA, Z) is also essential in the treatment of multidrug-resistant (MDR)-TB.” PMID 26038418 ↗ Jul 2012 “Coadministering pyrazinamide (PZA) with the xanthine oxidase inhibitor” PMID 28739782 ↗ Sep 2017 “regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)” PMID 24903795 ↗ May 2014 “Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd” NCT02128308 ↗ “Drug: Pyrazinamide (PZA)” NCT05383742 ↗ “pyrazinamide (PZA \[Z\])” NCT02371681 ↗ “pyrazinamide (Z / PZA)” NCT02231229 ↗ “Pyrazinamide (PZA):” NCT07268664 ↗ “pyrazinamide [PZA]” NCT02365623 ↗ |
| Known as | Rozide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Tebrazid | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Unipyranamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Known as | Zinamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL614 ↗ |
| Action | Inhibit | “PZA acts differently from common antibiotics by inhibiting multiple targets such as energy production, trans-translation, and perhaps pantothenate/coenzyme A required for...” PMID 26104205 ↗ Aug 2014 |
| Modality | Small molecule | “is a synthetic derivative of nicotinamide” NCT00816426 ↗ |
| Route | Oral | “Pyrazinamide (PZA) will be dosed orally” NCT00816426 ↗ |